



## **Tolperison (Tolpermyo)**

Summary of recommendations by *Zorginstituut Nederland* dated 23 May 2016

*Zorginstituut Nederland* has drawn up a pharmacotherapeutic report for the medicine tolperison (Tolpermyo®), whereby it reached the following conclusion. Based on the criteria of the Medicines Reimbursement System (GVS), the *Zorginstituut* is of the opinion that tolperison is interchangeable with baclofen and tizanidine, and can therefore be included on List 1A of the GVS in cluster 0M03BXAV with a standard dose of 200 mg/day.

### **Background**

In a letter dated 7 March 2016 (CIBG-16-01790), the Minister of Health, Public Welfare and Sport asked *Zorginstituut Nederland* to assess whether tolperison (Tolpermyo®) is interchangeable with a drug that is included in the GVS system. With the assistance of the Scientific Advice Board (WAR), the *Zorginstituut* has now completed its assessment.

### **Background**

Tolperison is available as 50 mg and 150 mg film-coated tablets. It is indicated for the symptomatic treatment of spasticity in adults following a stroke. The dose should be adjusted according to individual needs and tolerance. The daily dose is between 150 and 450 mg per day, divided in three doses.

### **Assessment of interchangeability**

Based on the current GVS criteria, tolperison (Tolpermyo®) can be regarded as interchangeable with baclofen and tizanidine, which have already been included on List 1A of the GVS in cluster 0M03BXAV.

### **Zorginstituut Nederland's advice**

Based on the above grounds, *Zorginstituut Nederland* advises the Minister of Public Health, Welfare and Sport to include tolperison on List 1A of the GVS in cluster 0M03BXAV, with a standard dose of 200 mg/day.

For further information, please contact: P.Pasman@zinl.nl; warcg@zinl.nl

*The original text of this advice of Zorginstituut Nederland was in Dutch. Although great care was taken in translating the text from Dutch to English, the translation may nevertheless have resulted in discrepancies. Rights may only be derived on the basis of the Dutch version of Zorginstituut Nederland's advice.*

*Furthermore, Zorginstituut Nederland points out that only the summary of this report was translated. A proper understanding of all relevant considerations and facts would require familiarity with the Dutch version of this report, including all appendices.*